Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Amortizatization of Intangibles (2019 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Amortizatization of Intangibles for 8 consecutive years, with $862000.0 as the latest value for Q1 2026.

  • For Q1 2026, Amortizatization of Intangibles fell 76.05% year-over-year to $862000.0; the TTM value through Mar 2026 reached $8.0 million, down 39.48%, while the annual FY2025 figure was $10.8 million, 20.16% down from the prior year.
  • Amortizatization of Intangibles hit $862000.0 in Q1 2026 for Syndax Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $4.0 million in Q1 2023 and bottomed at $53000.0 in Q1 2022.
  • Average Amortizatization of Intangibles over 5 years is $2.5 million, with a median of $3.1 million recorded in 2024.
  • Year-over-year, Amortizatization of Intangibles soared 7384.91% in 2023 and then tumbled 76.05% in 2026.
  • Syndax Pharmaceuticals' Amortizatization of Intangibles stood at $2.0 million in 2022, then soared by 70.81% to $3.5 million in 2023, then decreased by 15.0% to $2.9 million in 2024, then crashed by 47.96% to $1.5 million in 2025, then plummeted by 43.66% to $862000.0 in 2026.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods came in at $862000.0, $1.5 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.